CA2928773A1 - Cell transport - Google Patents

Cell transport Download PDF

Info

Publication number
CA2928773A1
CA2928773A1 CA2928773A CA2928773A CA2928773A1 CA 2928773 A1 CA2928773 A1 CA 2928773A1 CA 2928773 A CA2928773 A CA 2928773A CA 2928773 A CA2928773 A CA 2928773A CA 2928773 A1 CA2928773 A1 CA 2928773A1
Authority
CA
Canada
Prior art keywords
cpp
agent
therapeutic
molecule
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2928773A
Other languages
English (en)
French (fr)
Inventor
William Jonathan RYVES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CUPID PEPTIDE Co Ltd
Original Assignee
CUPID PEPTIDE COMPANY LIMITED
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CUPID PEPTIDE COMPANY LIMITED filed Critical CUPID PEPTIDE COMPANY LIMITED
Publication of CA2928773A1 publication Critical patent/CA2928773A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2928773A 2013-10-28 2014-10-09 Cell transport Pending CA2928773A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1318954.3A GB201318954D0 (en) 2013-10-28 2013-10-28 Cell transport
GB1318954.3 2013-10-28
PCT/GB2014/053037 WO2015063452A2 (en) 2013-10-28 2014-10-09 Cell transport

Publications (1)

Publication Number Publication Date
CA2928773A1 true CA2928773A1 (en) 2015-05-07

Family

ID=49767211

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2928773A Pending CA2928773A1 (en) 2013-10-28 2014-10-09 Cell transport

Country Status (6)

Country Link
US (1) US9913914B2 (enExample)
EP (1) EP3062822B1 (enExample)
JP (1) JP6576355B2 (enExample)
CA (1) CA2928773A1 (enExample)
GB (1) GB201318954D0 (enExample)
WO (1) WO2015063452A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018301651B2 (en) 2017-07-10 2023-05-18 Sri International A peptide saporin conjugate for the treatment of cancer
US11965004B2 (en) * 2017-07-10 2024-04-23 Sri International Molecular guide system peptides and uses thereof
JP2021531038A (ja) * 2018-07-13 2021-11-18 ザ、トラスティーズ オブ プリンストン ユニバーシティ ストレス顆粒集合を調節するためのシステム及び方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523359A (en) * 1995-01-13 1996-06-04 Exxon Chemical Patents Inc. Functionalized polymer and methods to obtain functionalized polymer
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
CA2350919A1 (en) 1998-11-13 2000-05-25 Cyclacel Limited Antennapedia homeodomain helix 3 derived translocation vectors
US7091026B2 (en) * 2001-02-16 2006-08-15 University Of Iowa Research Foundation Artificial endonuclease
GB0229151D0 (en) * 2002-12-13 2003-01-15 St Georges Entpr Ltd Product and method
WO2005016387A2 (en) * 2003-08-12 2005-02-24 University Of Iowa Research Foundation Dna-dependent mri contrast agents
WO2007097561A1 (en) * 2006-02-20 2007-08-30 Ewha University - Industry Collaboration Foundation Peptide having cell membrane penetrating activity
WO2007109908A1 (en) * 2006-03-29 2007-10-04 The University Of British Columbia Therapeutic yb-1 phosphorylation decoys
WO2012023284A1 (en) 2010-08-20 2012-02-23 Oncotherapy Science, Inc. Lhx4 as a target gene for cancer therapy and diagnosis
WO2012170431A2 (en) 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems

Also Published As

Publication number Publication date
EP3062822A2 (en) 2016-09-07
EP3062822B1 (en) 2025-05-14
EP3062822C0 (en) 2025-05-14
US20160310607A1 (en) 2016-10-27
JP2016535600A (ja) 2016-11-17
WO2015063452A2 (en) 2015-05-07
US9913914B2 (en) 2018-03-13
WO2015063452A3 (en) 2015-09-17
JP6576355B2 (ja) 2019-09-18
GB201318954D0 (en) 2013-12-11

Similar Documents

Publication Publication Date Title
Wang et al. Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapy
AU2021200135B2 (en) Liposome compositions and methods of use thereof
Deshayes et al. Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy
Futaki et al. Cell-surface interactions on arginine-rich cell-penetrating peptides allow for multiplex modes of internalization
Ruczynski et al. Cell-penetrating peptides as a promising tool for delivery of various molecules into the cells
US10131888B2 (en) Intracellular protein delivery
US9969774B2 (en) Cell penetrating peptide and method for delivering biologically active substance using same
JP2014159484A (ja) 細胞透過のための過剰に荷電されたタンパク質
JP2011523353A5 (enExample)
WO2014053629A1 (en) Cell penetrating peptides for intracellular delivery of molecules
Noguchi et al. Macropinocytosis-inducible extracellular vesicles modified with antimicrobial protein CAP18-derived cell-penetrating peptides for efficient intracellular delivery
JP2011137001A (ja) ポリヌクレオチドを送達する方法、及び送達用組成物
US9913914B2 (en) Cell transport
US20210269504A1 (en) Protein-based micelles for the delivery of hydrophobic active compounds
KR20150130249A (ko) 세포 투과성 펩티드 및 이를 이용한 생물학적 활성 물질의 전달방법
CN113966233A (zh) 用于基因编辑的细胞膜穿透缀合物
JP2020536582A (ja) 遺伝子発現抑制剤
Cahill Cell-penetrating peptides, electroporation and drug delivery
US12404307B2 (en) Methods and compositions for use of recombinant bacterial effector proteins as anti-inflammatory agents
US20230080270A1 (en) Nanoparticles encapsulating small molecules
US20240092837A1 (en) Novel Peptide Carrier Compositions
Palm-Apergi et al. A new rapid cell-penetrating peptide based strategy to produce bacterial ghosts for plasmid delivery
WO2021004923A1 (en) Cell penetrating peptides for intracellular delivery of molecules
WO2023153949A1 (en) Protein carrier system based on cyanobacterial nano-sized extracellular vesicles
Marchione et al. Study on the internalization mechanism of the ZEBRA cell-penetrating peptide

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190912

EEER Examination request

Effective date: 20190912

EEER Examination request

Effective date: 20190912

EEER Examination request

Effective date: 20190912

EEER Examination request

Effective date: 20190912

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240924

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240924

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240924

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250327

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250328